Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lifeward Ltd. filings on SEC EDGAR ↗
Lifeward Ltd. reported Q3 2026 financial results, highlighted by an 18% year-over-year increase in AlterG revenue to $3.6 million. The company is transitioning its ReWalk exoskeleton business to a capital-efficient channel-partner distribution model, including a pilot program with Ottobock Care, to expand patient access and reduce operating expenses.
Term
Q3 2026
“Our third quarter results reflect the continued momentum of AlterG, which delivered its second consecutive quarter of double-digit year-over-year revenue growth. We are also making significant progress in our strategic transition of ReWalk to a channel-partner model, which we believe is the most effective way to scale this business and bring our life-changing technology to more patients.”
Larry Jasinski, Chief Executive Officer
“We remain focused on driving commercial execution and managing our resources effectively as we advance our transition to a channel-partner model for ReWalk. We believe this model will allow us to reach more patients while improving our operating efficiency and cash flow over the long term.”
Lifeward Ltd. reported its financial results for the quarter ended September 30, 2026, highlighting the recent acquisition of Oratech Pharmaceuticals Ltd. and the ongoing transition to a channel-partner distribution model. The company expressed substantial doubt regarding its ability to continue as a going concern, noting the urgent need for additional financing to fund operations and clinical trials for ORMD-0801.
Lifeward Ltd. held its 2026 Annual and Extraordinary General Meeting of Shareholders on October 30, 2026. Shareholders approved the re-election of Haggai Zamir and Avi Gabay as Class III directors, the election of Ariel Kallner as an external director, and compensation packages for directors and Interim CEO Josh Hexter; however, Proposal 6 did not receive the requisite votes for approval.
Lifeward Ltd. appointed Ronen Tsimerman as Chief Financial Officer, effective November 1, 2026. The appointment includes an employment agreement with a gross monthly base salary of NIS 70,000 and a target annual performance-based bonus of at least four monthly salaries, subject to shareholder approval of a renewed compensation policy.